|
|
|
|
|
HOPE Research Institute is fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP). HOPE is the first independent, private clinical research site in the nation to receive this prestigious accreditation. AAHRPP accreditation confirms that standards for the protection of human study participants is paramount in study operations at HOPE.
The U.S. Food and Drug Administration has approved Multaq tablets (dronedarone) to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter (heart rhythm disorders). The drug is approved to be used in patients whose hearts have returned to normal rhythm or who will undergo drug or electric-shock treatment to restore a normal heart beat. Thu, 02 Jul 2009 14:39:00 UTC
FDA: Boxed Warning on Serious Mental Health Events to be Required for Chantix and Zyban
The U.S. Food and Drug Administration today announced that it is requiring manufacturers to put a Boxed Warning on the prescribing information for the smoking cessation drugs Chantix (varenicline) and Zyban (bupropion). The warning will highlight the risk of serious mental health events including changes in behavior, depressed mood, hostility, and suicidal thoughts when taking these drugs. Wed, 01 Jul 2009 16:17:00 UTC
FDA Seeks Public Input on Tobacco Regulation
The U.S. Food and Drug Administration announced today that it is seeking public input on the implementation of its historic new authority overseeing tobacco products in the United States. In a Federal Register notice, the agency invites the public to provide information and share views on a wide range of topics, from product content to advertising and marketing. Tue, 30 Jun 2009 16:37:00 UTC
National Institutes of Health News Releases
